Abstract
Purpose :
To analyze postsurgical outcomes for sequential canaloplasty and trabeculotomy with the OMNI surgical system (Sight Sciences, Inc) in patients with uveitic glaucoma.
Methods :
This is a retrospective, multicenter, single-arm study conducted at 3 institutions. Consecutive eligible patients had a diagnosis of uveitic glaucoma and were treated with canaloplasty and trabeculotomy using the OMNI surgical system (Sight Science, Inc).
Postoperative intraocular pressure less than or equal to 21 mmHg with or without medications and no additional surgery defined success through one year if available.
Results :
Fifteen eyes of 14 patients were included in the analysis. The median age at surgery was 58 years (range: 15-76), with 46.6% representing right eyes and 42.8% being male. The median canaloplasty treatment was 180°, and the median goniotomy treatment was 360°. Median follow-up duration was 12.5 months (range: 1.0-21.0). Median preoperative IOP was 30.0 mm Hg (range: 11.0-49.0 mm Hg), decreasing to a median final postoperative IOP of 13.0 mm Hg (range: 3.0-21.0 mm Hg). The median number of preoperative glaucoma medications was 5.5 (range: 1.0-8.0), while the median number at the final postoperative visit was 1.0 (range: 0-4.0). Complications included three eyes requiring an Ahmed glaucoma valve implant, and one that underwent an anterior chamber washout. Success was achieved in 73.3% of eyes.
Conclusions :
This study presents a retrospectively collected dataset on canaloplasty and trabeculotomy, offering valuable insights into their utility for uveitic glaucoma. Limited data are available on the use of these procedures in uveitic glaucoma patients. The OMNI surgical system (Sight Sciences, Inc) may be effective for uveitic glaucoma patients as it targets the diseased tissue thought to be damaged during chronic inflammation. The system also demonstrates a favorable safety profile, suggesting its potential as an alternative to traditional glaucoma filtration surgery.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.